Peppy Rebello

Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes

Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Medicine, Endocrinology, Immunology +17

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 499 citations · Full text

Medicine, Hematology, Oncology +16

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Emma Morris, Peppy Rebello, Kirsty Thomson et al. · Blood · 2003 · 193 citations

Life Sciences, Immunology, Pharmacokinetics +17

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

G Hale, Peppy Rebello, Lee Brettman et al. · Blood · 2004 · 182 citations · Full text

Pharmacy, Immunology, Oncology +14

Pharmacokinetics of CAMPATH-1H: assay development and validation

Peppy Rebello, G Hale · Journal of Immunological Methods · 2002 · 85 citations

Medicine, Pharmacokinetics, Pharmacology +7